Morphic Therapeutic
Morphic Therapeutic develops oral integrin therapies that target chronic diseases by modulating immune responses through specific integrin interactions. This approach aims to improve patient outcomes by providing a more effective and convenient treatment option compared to traditional intravenous therapies.
- Biotechnology
Funding
Raised to date
$276MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many chronic diseases, particularly those involving immune responses, are treated with intravenous therapies, which can be inconvenient and less effective for patients. These traditional treatments often require frequent clinic visits and may not precisely target the underlying mechanisms of the disease.
Solution
Morphic Therapeutic develops oral integrin therapies designed to target and modulate immune responses at the source of chronic diseases. By focusing on specific integrin interactions, their approach aims to provide a more effective and convenient treatment option compared to traditional intravenous methods. These oral therapies offer the potential for improved patient outcomes through targeted modulation of immune responses, reducing the burden of frequent infusions and enhancing treatment precision. The company leverages extensive expertise in integrin biology to create novel therapeutics that address the unmet needs of patients with chronic conditions.
Target Audience
The primary target audience includes patients suffering from chronic diseases requiring immune modulation, as well as healthcare providers seeking more effective and convenient treatment options.
Features
- Development of oral integrin therapies for chronic diseases.
- Targeted modulation of immune responses through specific integrin interactions.
- Focus on creating convenient and effective treatment options compared to intravenous therapies.
- Expertise in integrin biology to design novel therapeutics.